News stories about Horizon Pharma (NASDAQ:HZNP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Horizon Pharma earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.2648880494356 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Horizon Pharma (HZNP) opened at $14.14 on Friday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.54 and a current ratio of 1.63. The firm has a market capitalization of $2,397.78, a PE ratio of -5.61, a price-to-earnings-growth ratio of 0.62 and a beta of 1.34. Horizon Pharma has a twelve month low of $9.45 and a twelve month high of $16.02.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.07. The firm had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. The company’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 earnings per share. equities analysts predict that Horizon Pharma will post 1.43 EPS for the current year.

Several research analysts have recently issued reports on HZNP shares. Mizuho upgraded Horizon Pharma from a “neutral” rating to a “buy” rating and raised their price target for the stock from $12.00 to $18.00 in a research report on Friday, January 12th. Cantor Fitzgerald set a $17.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research report on Wednesday, February 28th. BidaskClub lowered Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, February 21st. Cowen restated a “buy” rating and issued a $24.00 price target on shares of Horizon Pharma in a research report on Thursday, March 1st. Finally, UBS set a $20.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $18.64.

ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/horizon-pharma-hznp-getting-somewhat-favorable-press-coverage-study-finds/1958728.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Insider Buying and Selling by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.